FORECAST: HEAD AND NECK CANCER
Executive Summary
Market Overview and Trends
Market Definition and Methodology
durvalumab
Erbitux (cetuximab)
Gilotrif (afatinib)
Javlor (vinflunine ditartrate)
Keytruda (pembrolizumab)
Multikine
Opdivo (nivolumab)
Reolysin
TS-1 (gimeracil/oteracil potassium/tegafur)
Primary Research Methodology
TREATMENT: HEAD AND NECK CANCER
Executive Summary
Primary Research Methodology
Disease Definition and Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
EPIDEMIOLOGY: HEAD AND NECK CANCER
Executive Summary
Disease Background
Methodology
Forecast
Epidemiologist Insight
Strengths and Limitations
Bibliography
Appendix: Additional Sources
MARKETED DRUGS: HEAD AND NECK CANCER
Executive Summary
Product Overview
Product profile: Erbitux
PIPELINE: HEAD AND NECK CANCER
Executive Summary
Clinical Pipeline Overview
Recently Discontinued Drugs
Comparator Therapy
Product profile (late stage): Gilotrif
Product profile (late stage): Javlor
Product profile (late stage): Keytruda
Product profile (late stage): Multikine
Product profile (late stage): Opdivo
Product profile (late stage): Reolysin
Product profile (late stage): durvalumab

LIST OF FIGURES
Figure 1: SCCHN drug sales in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 2: SCCHN drug sales in the US, Japan, and five major EU markets, by status ($m), 2015-24
Figure 3: SCCHN drug sales in the US, by status ($m), 2015-24
Figure 4: SCCHN drug sales in Japan, by status ($m), 2015-24
Figure 5: SCCHN drug sales in the five major EU markets, by status ($m), 2015-24
Figure 6: Methodology flow
Figure 7: Price sources and calculations, by country
Figure 8: Durvalumab sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 9: Erbitux sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 10: Gilotrif sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 11: Javlor sales forecast for SCCHN in the five major EU markets, by country ($m), 2015-24
Figure 12: Keytruda sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 13: Multikine sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 14: Opdivo sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 15: Reolysin sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 16: TS-1 sales forecast for SCCHN in Japan ($m), 2015-24
Figure 17: HPV screening rates and outcomes among SCCHN patients, by country
Figure 18: Proportion of prevalent SCCHN patients in each stage of disease, by country
Figure 19: Proportion of Stage I and Stage II SCCHN patients receiving each treatment type, by country
Figure 20: Percentage of Stage III SCCHN patients receiving each treatment type, by country
Figure 21: Percentage of Stage III SCCHN patients receiving neoadjuvant therapy, adjuvant therapy, or both, by country
Figure 22: Top three regimens used in the adjuvant treatment of Stage III SCCHN patients, by country
Figure 23: Percentage of Stage IV SCCHN patients receiving each treatment type, by country
Figure 24: Top three regimens used in the first-line treatment of Stage IV SCCHN patients who receive pharmacological therapy without surgery, by country
Figure 25: Percentage of Stage IV SCCHN patients who progress from first- to second-line therapy or from second- to thirdline therapy, by country
Figure 26: Top three regimens used for the second-line treatment of Stage IV SCCHN patients, by country
Figure 27: Percentage of local relapse SCCHN patients receiving each treatment type, by country
Figure 28: Top three regimens used in the first-line treatment of local relapse SCCHN patients receiving pharmacological therapy without surgery, by country
Figure 29: Top three regimens used in the second-line treatment of local relapse SCCHN patients, by country
Figure 30: Percentage of distant relapse SCCHN patients receiving each treatment type, by country
Figure 31: Top three regimens used in the first-line treatment of distant relapse SCCHN patients who receive pharmacological therapy without surgery, by country
Figure 32: Top three regimens used in the second-line treatment of distant relapse SCCHN patients, by country
Figure 33: Trends in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
Figure 34: Absolute change in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
Figure 35: Age-specific trends in incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
Figure 36: Erbitux for head and neck cancer - SWOT analysis
Figure 37: Datamonitor Healthcare's drug assessment summary of Erbitux for head and neck cancer
Figure 38: Datamonitor Healthcare's drug assessment summary of Erbitux for head and neck cancer
Figure 39: Gilotrif for head and neck cancer - SWOT analysis
Figure 40: Datamonitor Healthcare's drug assessment summary of Gilotrif for head and neck cancer
Figure 41: Datamonitor Healthcare's drug assessment summary of Gilotrif for head and neck cancer
Figure 42: Javlor for head and neck cancer - SWOT analysis
Figure 43: Datamonitor Healthcare's drug assessment summary of Javlor for head and neck cancer
Figure 44: Datamonitor Healthcare's drug assessment summary of Javlor for head and neck cancer
Figure 45: Keytruda for head and neck cancer - SWOT analysis
Figure 46: Datamonitor Healthcare's drug assessment summary of Keytruda for head and neck cancer
Figure 47: Datamonitor Healthcare's drug assessment summary of Keytruda for head and neck cancer
Figure 48: Multikine for head and neck cancer - SWOT analysis
Figure 49: Datamonitor Healthcare's drug assessment summary of Multikine for head and neck cancer
Figure 50: Datamonitor Healthcare's drug assessment summary of Multikine for head and neck cancer
Figure 51: Opdivo for head and neck cancer - SWOT analysis
Figure 52: Datamonitor Healthcare's drug assessment summary of Opdivo for head and neck cancer
Figure 53: Datamonitor Healthcare's drug assessment summary of Opdivo for head and neck cancer
Figure 54: Reolysin for head and neck cancer - SWOT analysis
Figure 55: Datamonitor Healthcare's drug assessment summary of Reolysin for head and neck cancer
Figure 56: Datamonitor Healthcare's drug assessment summary of Reolysin for head and neck cancer
Figure 57: Durvalumab for head and neck cancer - SWOT analysis
Figure 58: Datamonitor Healthcare's drug assessment summary of durvalumab for head and neck cancer
Figure 59: Datamonitor Healthcare's drug assessment summary of durvalumab for head and neck cancer

LIST OF TABLES
Table 1: SCCHN drug sales in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 2: SCCHN drug sales in the US, Japan, and five major EU markets, by brand and status ($m), 2015-24
Table 3: SCCHN drug sales in the US, by brand and status ($m), 2015-24
Table 4: SCCHN drug sales in Japan, by brand and status ($m), 2015-24
Table 5: SCCHN drug sales in the five major EU markets, by brand and status ($m), 2015-24
Table 6: Summary of drug classes, molecules, and brands included in the SCCHN patient-based forecast
Table 7: Exchange rates used for calculating prices
Table 8: Patent expiry dates for key marketed brands in SCCHN, by region
Table 9: Estimated approval dates of key late-stage pipeline products in SCCHN, by region
Table 10: Durvalumab sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 11: Durvalumab patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 12: Erbitux sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 13: Erbitux patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 14: Gilotrif sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 15: Gilotrif patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 16: Javlor sales forecast for SCCHN in the five major EU markets, by country ($m), 2015-24
Table 17: Javlor patient numbers for SCCHN in the five major EU markets, by country, 2015-24
Table 18: Keytruda sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 19: Keytruda patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 20: Multikine sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 21: Multikine patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 22: Opdivo sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 23: Opdivo patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 24: Reolysin sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 25: Reolysin patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 26: TS-1 sales forecast for SCCHN in Japan ($m), 2015-24
Table 27: TS-1 patient numbers for SCCHN in Japan, 2015-24
Table 28: Physicians surveyed for the squamous cell carcinoma of the head and neck primary research study, 2015
Table 29: Physicians surveyed for the head and neck cancer primary research study, 2017
Table 30: Oral cavity and pharynx cancer five-year survival rates, by stage at diagnosis, 2007-13
Table 31: TNM stage classification
Table 32: Leading treatments for SCCHN
Table 33: Head and neck cancer site codes according to ICD-10
Table 34: Cancer registry databases used as a source of HNC incidence data, by country
Table 35: Forecasting methodology for HNC incidence, by country, age group, and gender
Table 36: Sources of survival data used to estimate HNC prevalence, by country/region
Table 37: Diagnosed incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
Table 38: Age-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
Table 39: Gender-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
Table 40: Validation of forecast estimates against benchmark estimates
Table 41: Key marketed drugs for head and neck cancer
Table 42: Erbitux drug profile
Table 43: Erbitux pivotal trial data in head and neck cancer
Table 44: Late-stage pipeline products in development for head and neck cancer
Table 45: Late-stage compounds that were recently discontinued for head and neck cancer
Table 46: Erbitux drug profile
Table 47: Gilotrif drug profile
Table 48: Gilotrif Phase III trials in head and neck cancer
Table 49: Gilotrif Phase III data in head and neck cancer
Table 50: Javlor drug profile
Table 51: Javlor Phase III trials in head and neck cancer
Table 52: Keytruda drug profile
Table 53: Keytruda Phase III trials in head and neck cancer
Table 54: Keytruda topline early-phase data in head and neck cancer
Table 55: Overview of Phase Ib trial data for Keytruda in PD-L1-positive head and neck cancer patients
Table 56: Multikine drug profile
Table 57: Multikine Phase III trials in head and neck cancer
Table 58: Overview of Phase II trial data for Multikine in head and neck cancer
Table 59: Opdivo drug profile
Table 60: Ongoing Opdivo Phase III trials in head and neck cancer
Table 61: Opdivo Phase III data in head and neck cancer
Table 62: Reolysin drug profile
Table 63: Reolysin Phase III data in head and neck cancer
Table 64: Durvalumab drug profile
Table 65: Durvalumab Phase III and pivotal Phase II trials in head and neck cancer